SOP Guide for Pharma

BA-BE Studies: SOP for Short-Term Stability of Analyte – V 2.0

BA-BE Studies: SOP for Short-Term Stability of Analyte – V 2.0

Standard Operating Procedure for Short-Term Stability of Analyte in BA/BE Studies

Department BA-BE Studies
SOP No. SOP/BA-BE/175/2025
Supersedes SOP/BA-BE/175/2022
Page No. Page 1 of 9
Issue Date 17/04/2025
Effective Date 20/04/2025
Review Date 17/04/2026

1. Purpose

To define the procedure for conducting short-term stability studies of analytes in plasma to ensure sample integrity during temporary exposure to room temperature conditions during sample processing in bioavailability/bioequivalence (BA/BE) studies.

2. Scope

This SOP applies to the assessment of short-term stability of plasma samples stored temporarily at room temperature (~25°C) during processing and prior to injection into the LC-MS/MS system in BA/BE studies.

3. Responsibilities

  • Analyst: Prepares and processes QC samples for short-term stability study.
  • Reviewer: Verifies the results and compliance with acceptance criteria.
  • QA Officer: Reviews and approves documentation and ensures adherence to regulatory guidance.

4. Accountability

The Head of the Bioanalytical Department is accountable for ensuring correct execution, interpretation, and documentation of short-term stability data in accordance with ICH M10 and other applicable guidelines.

5. Procedure

5.1 Sample Preparation

  1. Prepare a minimum of six replicates of Low QC (LQC) and High QC (HQC) levels.
  2. Aliquot the prepared samples in appropriately labeled tubes indicating:
    • Study Code
    • Analyte
    • QC Level
    • Short-Term Stability
    • Date and Time
  3. Store one set under standard frozen condition (control) and another set at room temperature (~25°C).

5.2 Exposure Duration

  1. Keep stability sample set at ambient temperature for a pre-defined duration:
    • Typically 4, 6, or 24 hours depending on method validation protocol.
  2. After the exposure period, return the samples to -20°C until analysis.

5.3 Sample Analysis

  1. Analyze short-term exposed samples with freshly prepared calibration standards and frozen control QCs using validated LC-MS/MS method.
  2. Document retention time, area counts, and concentration of each replicate.

5.4 Acceptance Criteria

  1. Mean measured concentration of LQC and HQC should be within ±15% of nominal values.
  2. %CV should be ≤15% across replicates at each QC level.
  3. Record and compare results in Annexure-1: Short-Term Stability Summary.

5.5 Reporting

  1. Document observations and outcomes in the short-term stability report.
  2. Submit report to QA for review and approval.
  3. Include stability report as part of the method validation or study report.

6. Abbreviations

  • BA/BE: Bioavailability/Bioequivalence
  • LQC: Low Quality Control
  • HQC: High Quality Control
  • %CV: Percent Coefficient of Variation
  • QA: Quality Assurance

7. Documents

  1. Short-Term Stability Summary – Annexure-1
  2. Chromatographic Data and Calibration Curves

8. References

  • ICH M10: Bioanalytical Method Validation
  • US FDA Guidance for Bioanalytical Method Validation
  • Method Validation Protocol

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Short-Term Stability Summary

QC Level Nominal (ng/mL) Mean Measured %CV % Difference Status
LQC 20.0 19.1 5.2 -4.5% Accepted
HQC 1500.0 1492.3 2.7 -0.5% Accepted

Revision History:

Revision Date Revision No. Details Reason Approved By
01/01/2022 1.0 Initial SOP Issue New Procedure QA Head
17/04/2025 2.0 Updated to align with ICH M10 and clarified %CV requirement Regulatory Update QA Head
Exit mobile version